Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients

Amanda Cheung, Carlos Figueredo, Mary Eugenia Rinella*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations


Nonalcoholic fatty liver disease (NAFLD) is an increasingly dominant cause of liver disease worldwide. The progressive subtype, nonalcoholic steatohepatitis, is a leading indication for liver transplantation and a noteworthy cause of hepatocellular carcinoma. The overall prevalence of NAFLD is on the rise, and even more concerning data modeling predicts that an increasing percentage of those with NAFLD will develop advanced disease. This increased volume of patients with advanced liver disease will impose a significant health care burden in terms of resources and cost. Thus, the identification of patients with established fibrosis or at high risk of developing advanced liver disease is critical to effectively intervene and prevent overall and liver-related morbidity and mortality. Herein, we provide a framework to consider for the identification of patients with NAFLD at high risk of nonalcoholic steatohepatitis with advanced fibrosis and provide a critical assessment of currently accessible diagnostic and treatment modalities.

Original languageEnglish (US)
Pages (from-to)579-590
Number of pages12
JournalAmerican Journal of Gastroenterology
Issue number4
StatePublished - Apr 1 2019

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients'. Together they form a unique fingerprint.

Cite this